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Abstract The purpose of this paper is to review the basic
science and clinical literature on scaffolds clinically
available for the treatment of articular cartilage injuries.
The use of tissue-engineered grafts based on scaffolds
seems to be as effective as conventional ACI clinically.
However, there is limited evidence that scaffold techniques
result in homogeneous distribution of cells. Similarly, few
studies exist on the maintenance of the chondrocyte phe-
notype in scaffolds. Both of which would be potential
advantages over the ﬁrst generation ACI. The mean clinical
score in all of the clinical literature on scaffold techniques
signiﬁcantly improved compared with preoperative values.
More than 80% of patients had an excellent or good out-
come. None of the short- or mid-term clinical and
histological results of these tissue-engineering techniques
with scaffolds were reported to be better than conventional
ACI. However, some studies suggest that these methods
may reduce surgical time, morbidity, and risks of periosteal
hypertrophy and post-operative adhesions. Based on the
available literature, we were not able to rank the scaffolds
available for clinical use. Firm recommendations on which
cartilage repair procedure is to be preferred is currently not
known on the basis of these studies. Randomized clinical
trials and longer follow-up periods are needed for more
widespread information regarding the clinical effectiveness
of scaffold-based, tissue-engineered cartilage repair.
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Introduction
The repair of articular cartilage defects in the knee of
young or active individuals remains a problem in ortho-
pedic practice. These defects have limited ability to heal
and may progress to osteoarthritis. They may be symp-
tomatic and cause pain, swelling and catching. In a study of
993 consecutive arthroscopies done in patients with knee
pain [2], articular cartilage changes were noted in 66% of
the knees and isolated, localized cartilage lesions in about
20% of the cases. Full thickness cartilage lesions were
found in 11% of the knees and 6% were larger than 2 cm
2.
Several different surgical procedures have been applied
to treat cartilage injuries, but no method has been judged
superior. At present, more than 5,000 Medline citations are
available on surgical cartilage treatment. Microfracture
technique, as a low cost and minimally invasive procedure,
is currently being used as the ﬁrst choice in patients
with previously untreated cartilage defects. However, his-
tological analysis of repair tissue after these operations
shows mainly ﬁbrocartilage. Advantages of mosaicplasty
or osteochondral autologous grafts are that defects can be
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DOI 10.1007/s00167-008-0663-2ﬁlled immediately with mature, hyaline articular cartilage
and that both chondral and osteochondral defects can be
treated in the same way. However, donor site morbidity is a
concern and the long-term results of the harvesting pro-
cedure are not known. Of the numerous techniques
available today, no method has yet been able to consis-
tently reproduce normal hyaline cartilage. One such
method is autologous chondrocyte implantation (ACI),
described by Brittberg et al. in 1994 [11]. The introduction
of ACI into clinical practice has enabled the application of
tissue-engineering techniques with a cell-based therapy
that allows regeneration of damaged cartilage tissue.
Although the short- or middle-term clinical results of ACI
were reported as good [74, 87], this procedure has potential
disadvantages, such as the risk of leakage of transplanted
chondrocytes from the cartilage defects, an uneven distri-
bution of chondrocytes in the transplanted site due to
gravity [101], periosteal hypertrophy [42, 104], complexity
of the surgical procedure [67], and not the least the reac-
quisition of phenotypes of dedifferentiated chondrocytes in
a monolayer culture [8, 59].
In order to overcome some of these hurdles,
researchers have attempted to reconstruct cartilage in the
laboratory using tissue engineering, a technique by which
a living tissue can be reconstructed by associating the
cells with biomaterials that provide a scaffold on which
they can proliferate three-dimensionally, under physio-
logical conditions. The scaffold technique may have the
technical and theoretical advantages such as less invasive
technique because of no need to harvest periosteum, as
well as homogeneous distribution of chondrocytes and
the maintenance of the phenotype. Carriers have been
marketed and various tissue-engineering techniques,
widely used nowadays, have been developed using
chondrocytes seeded on biological matrices such as col-
lagen membranes [22] or hyaluronic acid [67]. Despite
the diffusion of these methods, the ideal matrix material
has not been identiﬁed, and there are still some areas that
would need better clariﬁcation. It has not veriﬁed that the
technical and theoretical advantages of scaffold tech-
niques have led to the better clinical and histological
results compared with conventional ACI. Therefore, a
review of current developments in scaffolds for cartilage
tissue engineering in clinical use and future perspectives
are necessary.
The aim of this review is to assess the literature of
clinically available scaffolds used for the treatment of
articular cartilage injuries in order to know the current
status of scaffolds for cartilage tissue engineering.
Although tissue engineering consists of three major parts;
transplanted cells, scaffold for cell proliferation, and
growth factors, we focus on the literature on scaffolds in
clinical use. In addition, this article details the evidence
from studies on the clinical outcome of tissue-engineered
cartilage repair. The main questions to be answered are:
do advanced cartilage tissue-engineering grafts ensure
even distribution of a high number of vital chondrocytes,
mediate initial biomechanical stability, promote chon-
drocyte differentiation and the formation of cartilage
matrix, thereby yielding better clinical outcomes with
decreased complications, compared with conventional
ACI?
Current cartilage repair strategies and tissue
engineering
Historical unsatisfactory results of cartilage injury reﬂect
the poor healing capacity of cartilage arising from its iso-
lation from systemic regulation, and its lack of vessels and
nerve supply [66]. None of the normal inﬂammatory and
reparative processes is available for its repair. Furthermore,
chondrocytes which are surrounded by an extracellular
matrix cannot migrate to the site of injury from an intact
healthy site, unlike most tissues [16]. Injuries which reach
the subchondral bone may induce a systemic reaction and
generate reparative tissue. The new tissue consists pre-
dominantly of type I collagen, resulting in the formation of
ﬁbrocartilage. Type I collagen does not have the biome-
chanical properties of articular cartilage. Accordingly, it
cannot function as normal hyaline cartilage and eventually
degenerates [32].
ACI was ﬁrst described in 1994 [11]. The procedure
involves the patient having to undergo harvesting through
an arthroscopic procedure, followed 2–8 weeks later an
arthrotomy, where the cells are injected under a cover of
periosteum. The original ACI technique involved the
injection of a suspension of cultured chondrocytes into a
debrided chondral defect beneath a periosteal cover. Clin-
ical results from femoral defects have ranged from 60 to
90% excellent and good between 1 to 11 years after sur-
gery [7, 11, 14, 26, 37, 44, 46, 47, 51, 61, 62, 73, 74, 76,
77, 87–89].
As mentioned, the ACI procedure has several disad-
vantages. Especially, hypertrophy of tissue seemed to be
the major cause for re-operations after ACI [37, 42, 78,
104]. Using collagen membranes instead of periosteum
could possibly reduce the risk for re-operations. Several
studies showed a lower incidence of graft hypertrophy after
ACI with a type I/III collagen membrane [7, 10, 37, 42, 63,
104]. As further technological advances, researchers have
initiated the use of carrier i.e., a scaffold or matrix upon
which the cells are grown. The use of three-dimensional
scaffolds has enabled maintenance of a chondrocyte dif-
ferentiated phenotype. A further advantage of this method
of cell delivery is that the scaffold may act as a barrier
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123to the invasion of the graft by ﬁbroblasts, which may
otherwise induce ﬁbrous repair [29]. In addition, most of
the articular cartilage engineering techniques with scaf-
folds can be done without a periosteal or membrane
coverage and in many cases using arthroscopic techniques.
Consequently, the procedures may be performed faster and
with a less extensive exposure.
Scaffolds available for clinical application
The scaffold must be biocompatible, structurally and
mechanically stable, must support the loading of an
appropriate cell source to allow successful inﬁltration and
attachment with appropriate bioactive molecules in order
to promote cellular differentiation and maturation, and
must be biodegradable, giving temporary support. Several
natural biomaterials, such as collagen [20, 98, 116], hya-
luronan [39], ﬁbrin glue [48, 50], alginate [3, 41, 43, 72,
96, 106], agarose [8, 92, 105], or chitosan [99], as well as
synthetic biomaterials such as polylactic acid [23] have
been developed for the restoration of damaged cartilage.
However, the clinical use of these materials is currently
limited, mainly due to the risk of disease transmission and
immunoreaction.
The inclusion criteria for studies on scaffolds available
for clinical application were use of in vitro or in vivo or
clinical studies on scaffolds with clinical trial. Several
studies on scaffolds such as alginate, agarose and chitosan
were excluded because of no clinical experience. Ulti-
mately studies on collagen, hyaluronan-based polymer,
ﬁbrin, and synthetic copolymer scaffold were included in
this review based on the inclusion criteria. Collagen and
hyaluronan-based matrices are among the most popular
natural scaffolds in clinical use nowadays, as they offer a
substrate that would normally be found in the structure of
native articular cartilage. Our literature searches are based
on MEDLINE In-process and other Non-Indexed Citations,
EMBASE, and CINAHL using Ovid searches of articles
published between 1 January 1966, and 1 March 2008.
Therefore, we acknowledge that the most important limi-
tation of this study is the limitation of the already existing
studies.
A bilayer collagen type I–III membrane
Collagen is one of matrix proteins occurring as a major
component of connective tissues, giving it strength and
stability. Collagen scaffolds have been used extensively for
cartilage regeneration for decades [19, 20, 38, 98, 116,
117]. Collagen can be fabricated as a membrane, gel,
sponge or foam and is subject to enzymatic degradation.
Matrix-induced ACI (MACI
; Verigen, Leverkusen, Ger-
many) can be considered as an evolution of conventional
ACI. The MACI technique is a tissue-engineering tech-
nique in which the principle of autologous cell culture is
preserved: a bilayer collagen I–III scaffold is used to
improve the structural and biological properties of the
graft. MACI uses processed cells that are harvested and
isolated from the patient and expanded in vitro. Once
grown, the chondrocytes are seeded between layers of a
bilaminate collagen in the operating room prior to
implantation. The MACI membrane can be secured directly
to the base of a prepared chondral defect by ﬁbrin glue and
without a cover. The surgical procedure is quite simple,
requiring short operating time. The MACI technique was
introduced in 1999 (Fig. 1)[ 22].
Other MACI membranes such as Maix
 (Matricel,
Hezoenrath, Germany) or Chondro-Gide
 (Geistlich Bio-
materials,Wolhusen, Switzerland) consist of a porcine
type I/type III collagen bilayer seeded with chondrocytes.
These membranes are degraded by enzymatic digestion
and have two different surfaces: the external has good
mechanical strength and serves as a barrier, whereas the
inner surface is porous and stimulates the cells to produce
cartilage-speciﬁc matrix molecules [33]. This membrane
has been used extensively in dental and maxillofacial
surgery since 1980 [24]. A number of in vitro and in vivo
studies have demonstrated that this multilayer three-
dimensional scaffold is an excellent medium for cell
attachment, maintaining the phenotype of chondrocytes
Fig. 1 The matrix-induced autologous chondrocyte implantation
procedure. Reprinted by permission from Cherubino et al. [22]
‘‘Autologous chondrocyte implantation using a bilayer collagen
membrane: a preliminary report. J Orthop Surg (Hong Kong)
11:10–15’’
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123overtime as well as delivering a dense superﬁcial layer to
keep the cells in the defect and limit the migration of
inﬂammatory proteins into the repair site. [27, 29, 33, 34,
55, 79–81, 118]. Furthermore, in a recent sheep study,
a multidefect cartilage repair model demonstrated that
collagen matrix seeded with autologous chondrocytes
produced better quantitative and qualitative results com-
pared with microfracture [25].
Gigante et al. [35] analyzed the distribution, viability
and phenotype expression of human chondrocytes seeded
on a collagen membrane at the time of the implantation.
The residual part of each membrane from 12 patients who
underwent MACI was tested by colorimetric assay and
histochemical and ultrastructural analyses were carried out.
In all of the samples a large number of viable cells, hom-
ogenously distributed, were detected. The cells expressed
the markers of the differentiated hyaline-producing chon-
drocytes [35].
Collagen type I gel
Ochi et al. [83] reported seeding chondrocytes in atelo-
collagen
 (Koken Co Ltd, Tokyo, Japan), a type I collagen
gel, and culturing the construct in a regular culture dish for
4 weeks for clinical use. They choose atelocollagen, from
which telopeptides have been removed, because the anti-
genic determinants on the peptide chains of type I collagen
reside mainly in the telopeptide regions [31, 90]. Atelo-
collagen has been used clinically in plastic surgery and
dermatology [52]. Their in vitro and in vivo experimental
[53, 57, 114] results support the hypothesis that trans-
planting chondrocytes cultured in atelocollagen gel are
effective in repairing articular cartilage defects, not only
in animals but also in humans, by maintaining the chon-
drocyte phenotype, reducing the risk of leakage, and
distributing grafted cells evenly throughout the grafted site.
The disadvantage is that the cell/gel construct needs to
be implanted under a periosteal cover to prevent it from
detaching.
Hyaluronan-based polymer
Hyaluronan (hyaluronic acid) is a major component of
cartilage matrix. The construct, a naturally occurring and
highly conserved glycosaminoglycan widely distributed in
the body, has proven to be an ideal molecule for tissue-
engineering strategies in cartilage repair, given its
impressive multi-functional activity in cartilage homeo-
stasis [21, 68]. Hyaluronan containing scaffolds such as
Hyaff-11
 (Fidia Advanced Biopolymers Laboratories,
Abano Terme, Italy), an esteriﬁed derivative of hyaluronan,
has a high degree of biocompatibility and can be used to
culture chondrocytes in three-dimensional culture condi-
tions that may effectively mimic an in vivo situation. It
fully resorbs in 3 months with controllable degradation
rates, with its main byproduct being hyaluronan, a sugar.
Hyalograft
 C (Fidia Advanced Biopolymers Laboratories,
Abano Terme, Italy) is a tissue-engineered graft consisting
of autologous chondrocytes grown on a Hyaff-11 scaffold
and a network of 20-lm-thick ﬁbers with interstices of
variable sizes. Articular cartilage is harvested from the
patient and grown in a two-dimensional culture in vitro.
Then the chondrocytes are absorbed onto a non-woven
pad made of the benzyl ester of hyaluronic acid. The
cells are seeded for 2 weeks on this hyaluronic acid
scaffold at a density of 1 million cells per cm
2, resulting
in a total of 4 million seeded cells per cm
2 per graft.
After 2 weeks, this construct is implanted into the knee.
In the majority of cases, no graft ﬁxation is required.
However, depending on the size and location of the
defect, ﬁbrin glue and/or sutures may be used to keep the
graft in place.
In vitro studies have shown that chondrocytes grown in
a three-dimensional matrix based on Hyaff-11 return
to their phenotype in a time-dependent manner, thus
restoring their capacity for secreting proteins and mole-
cules characteristic of a hyaline cartilage [1, 15, 40]. In
vivo studies in animal models have also shown that
hyaluronan-based scaffolds seeded with autologous
chondrocytes are useful for inducing formation of native,
hyaline-like cartilage tissue with integration with the
adjacent articular surface [39, 102, 103]. Extensive bio-
compatibility studies have demonstrated the safety of
biomaterials containing Hyaff-11 and their ability to be
resorbed in the absence of an inﬂammatory response [18].
Furthermore, Hyaff-11-based tissue-engineered cartilage
was assessed in an in vitro and in vivo setting with
respect to structure, biochemical composition and
mechanical behavior showing development and remodel-
ing of tissue-engineered cartilage [110]. Hyalograft C was
introduced into clinical use in 1999 [85]. Marcacci et al.
[67] have reported the use of an arthroscopic surgical
technique (Fig. 2).
Fibrin
Fibrin is a protein involved in the clotting of blood. It is
formed by polymerization of ﬁbrinogen in the presence of
thrombin usually at the wound site. Fibrin has been an
attractive biomaterial because it is biocompatible and
biodegradable. Injectable ﬁbrin-based gels or glues have
been investigated for cartilage repair [48, 50, 60]. How-
ever, in vivo animal studies have shown that cell migration
564 Knee Surg Sports Traumatol Arthrosc (2009) 17:561–577
123and tissue repair using such material appears to be limited
[12, 107]. The mechanical stability of ﬁbrin glue is ques-
tioned as well [107]; in addition, exogenous ﬁbrin may
trigger an immune response [58]. The action of ﬁbrin glue
on transplanted chondrocytes remains controversial.
Therefore, so far ﬁbrin glue has mainly been used clinically
to secure other tissue-engineered cartilage [22, 85], or
perichondrial scaffold grafts [9] etc. Visna et al. [115] has
reported 1-year clinical results of tissue-engineered carti-
lage repair using ﬁbrin glue (Tissucol
, BAXTER, Austria)
compared to abrasion technique.
Synthetic copolymer
The bioresorbable polymer scaffold in clinical use is the
copolymer of polyglycolic (PGA) / polylactic (PLA) acid
(polyglactin, vicryl) and polydioxanone, which is used for
tissue-engineered cartilage repair as Bio-Seed
-C (Biotis-
sue Technologies, Freiburg, Germany). The cartilage
tissue-engineering graft Bio-Seed-C combines autologous
chondrocytes with a ﬁbrin gel matrix in a porous three-
dimensional textile polymer scaffold. The organotypic cell
culture method with the cell-polymer tissues have been
shown to allow the in vitro production of bioartiﬁcial
cartilage for transplantation [17, 100]. Synthetic poly-a-
hydroxy ester substrates in the form of PGA and PLA-
based scaffolds have also shown to enhance the promotion
of proteoglycans, chondrocyte proliferation, differentiation
and maturation in comparison to collagen-based scaffolds
[38]. Gel-like matrices such as ﬁbrin allow even distribu-
tion of a large number of vital chondrocytes within the
graft and promote chondrocyte differentiation as well as
the formation of a cartilaginous repair tissue, while the
polymer scaffold mediates initial biomechanical stability
and allows easy handling of the graft by the surgeon [56].
Animal studies on rabbits and horses have shown formation
of a cartilaginous tissue and good integration into the
surrounding host tissue with ﬁrm bonding of the graft to the
adjacent cartilage and the underlying subchondral bone
[4, 86]. Such bioresorbable scaffold material has good
immunogenic compatibility, and is frequently used clini-
cally as suture material (polyglactin, vicryl). Various in
vitro and animal studies have shown that the scaffold
supports cartilaginous tissue development with no signs of
necrosis, apoptosis, or abnormal tissue reaction [4, 56, 84,
97]. Erggelet et al. [28] has reported a technical note of
using the polymer ﬂeece 2-mm thick, loaded with 5 9 10
6
chondrocytes in a ﬁbrin gel by arthroscopic technique in
2003. Further, Ossendorf et al. [84] has already shown
2-year clinical results on the use of the two component
gel-polymer scaffold.
Clinical outcomes of articular cartilage repair
with scaffolds
The inclusion criteria for clinical studies on scaffold
techniques were prospective or retrospective studies with a
clinical outcome. Fourteen studies were included in this
review based on the inclusion criteria (Tables 1, 2). Of
these, eight studies have been published including hyalu-
ronan-based scaffold (Hyalograft C) [36, 65, 68, 69, 71, 82,
85, 112]. Three studies have assessed the outcome of
MACI with a bilayer collagen type I–III membrane [5, 6,
22]. The remaining three studies have assessed the outcome
with a collagen type I gel, ﬁbrin glue, and synthetic
copolymer [83, 84, 115]. Only very limited number of
prospective, randomized or non-randomized comparative
studies have been published [5, 65, 115].The majority of
the published studies had no control group, represented
case series or retrospective level IV studies. As mentioned,
our literature searches are based on the articles published
between 1 January 1966, and 1 March 2008. Accordingly,
the most important limitation of this study is the limitation
of the already existing studies.
Clinical and functional scores
Encouraging clinical results have been published in terms
of various subjective and objective scores in all 14
available studies including arthroscopic technique [69]
and patello-femoral joint injury [36] (Table 1). According
to a prospective, randomized study by Visna et al. [115],
the use of tissue-engineered cartilage based on ﬁbrin glue
was superior to abrasion technique as measured by the
International Knee Documentation Committee (IKDC)
subjective score, Lysholm score, and Tengner activity
score 1 year after surgery. However, Manfredini et al.
[65] showed no signiﬁcant differences in International
Fig. 2 Arthroscopic autologous chondrocyte implantation using
Hyalograft C. Reprinted by permission from Marcacci et al. [67]
‘‘Arthroscopic autologous chondrocyte transplantation: Technical
note. Knee Surg Sports Traumatol. Arthrosc 10:154–159’’
Knee Surg Sports Traumatol Arthrosc (2009) 17:561–577 565
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o
n
,
(
p
\
0
.
0
0
7
)
S
t
a
t
i
s
t
i
c
a
l
l
y
s
i
g
n
i
ﬁ
c
a
n
t
i
m
p
r
o
v
e
m
e
n
t
s
w
e
r
e
o
b
s
e
r
v
e
d
(
p
\
0
.
0
5
)
–
–
K
O
O
S
;
T
h
e
p
a
t
i
e
n
t
’
s
s
t
a
t
u
s
h
a
d
i
m
p
r
o
v
e
d
s
i
g
n
i
ﬁ
c
a
n
t
l
y
(
p
\
0
.
0
5
)
T
r
a
t
t
n
i
g
e
t
a
l
.
[
1
1
2
,
1
1
3
]
R
e
t
r
o
s
p
e
c
t
i
v
e
,
c
r
o
s
s
-
s
e
c
t
i
o
n
a
l
H
y
a
l
u
r
o
n
a
n
(
H
y
a
l
o
g
r
a
f
t
C
)
1
5
3
–
4
2
m
o
n
t
h
s
–
–
–
–
–
B
r
i
t
t
b
e
r
g
s
c
o
r
e
;
E
x
c
e
l
l
e
n
t
o
r
G
o
o
d
:
8
0
%
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a
b
l
e
1
c
o
n
t
i
n
u
e
d
A
u
t
h
o
r
s
S
t
u
d
y
d
e
s
i
g
n
S
c
a
f
f
o
l
d
,
T
e
c
h
n
i
q
u
e
e
t
c
N
F
o
l
l
o
w
-
u
p
I
K
D
C
s
c
o
r
e
L
y
s
h
o
l
m
s
c
o
r
e
C
i
n
c
i
n
n
a
t
i
k
n
e
e
s
c
o
r
e
I
C
R
S
F
u
n
c
t
i
o
n
a
l
s
c
o
r
e
,
e
v
a
l
u
a
t
i
o
n
f
o
r
m
V
A
S
e
t
c
O
t
h
e
r
c
l
i
n
i
c
a
l
o
u
t
c
o
m
e
s
B
e
h
r
e
n
s
e
t
a
l
.
[
6
]
P
r
o
s
p
e
c
t
i
v
e
,
u
n
c
o
n
t
r
o
l
e
d
P
o
r
c
i
n
e
c
o
l
l
a
g
e
n
I
/
I
I
I
m
a
t
r
i
x
(
C
h
o
n
d
r
o
-
G
i
d
e
)
1
1
5
y
e
a
r
s
–
P
o
s
t
-
o
p
e
r
a
t
i
v
e
v
a
l
u
e
s
s
i
g
n
i
ﬁ
c
a
n
t
l
y
i
m
p
r
o
v
e
d
c
o
m
p
a
r
e
d
w
i
t
h
p
r
e
o
p
e
r
a
t
i
v
e
v
a
l
u
e
s
(
p
=
0
.
0
4
)
–
P
o
s
t
-
o
p
e
r
a
t
i
v
e
v
a
l
u
e
s
s
i
g
n
i
ﬁ
c
a
n
t
l
y
i
m
p
r
o
v
e
d
c
o
m
p
a
r
e
d
w
i
t
h
p
r
e
o
p
e
r
a
t
i
v
e
v
a
l
u
e
s
(
p
=
0
.
0
3
)
–
T
e
g
n
e
r
a
c
t
i
v
i
t
y
s
c
o
r
e
;
T
h
e
r
e
w
a
s
n
o
s
i
g
n
i
ﬁ
c
a
n
t
i
m
p
r
o
v
e
m
e
n
t
.
M
e
y
e
r
s
c
o
r
e
;
P
o
s
t
-
o
p
e
r
a
t
i
v
e
v
a
l
u
e
s
s
i
g
n
i
ﬁ
c
a
n
t
l
y
i
m
p
r
o
v
e
d
c
o
m
p
a
r
e
d
w
i
t
h
p
r
e
o
p
e
r
a
t
i
v
e
v
a
l
u
e
s
(
p
=
0
.
0
0
7
)
G
o
b
b
i
e
t
a
l
.
[
3
6
]
C
a
s
e
s
e
r
i
e
s
H
y
a
l
u
r
o
n
a
n
(
H
y
a
l
o
g
r
a
f
t
C
)
f
o
r
d
a
m
a
g
e
d
a
r
t
i
c
u
l
a
r
s
u
r
f
a
c
e
o
f
t
h
e
p
a
t
e
l
l
o
f
e
m
o
r
a
l
j
o
i
n
t
3
2
2
y
e
a
r
s
S
u
b
j
e
c
t
i
v
e
;
7
4
p
r
e
o
p
e
r
a
t
i
v
e
:
4
3
,
O
b
j
e
c
t
i
v
e
;
N
o
r
m
a
l
o
r
N
e
a
r
l
y
n
o
r
m
a
l
:
9
1
%
P
o
s
t
-
o
p
e
r
a
t
i
v
e
v
a
l
u
e
s
s
i
g
n
i
ﬁ
c
a
n
t
l
y
i
m
p
r
o
v
e
d
c
o
m
p
a
r
e
d
w
i
t
h
p
r
e
o
p
e
r
a
t
i
v
e
v
a
l
u
e
s
(
p
\
0
.
0
0
0
1
)
–
–
–
E
u
r
o
Q
o
l
-
E
Q
-
5
D
q
u
e
s
t
i
o
n
n
a
i
r
e
;
5
3
%
a
n
d
9
0
%
o
f
p
a
t
i
e
n
t
s
h
a
d
n
o
p
a
i
n
a
n
d
m
o
r
b
i
l
i
t
y
p
r
o
b
l
e
m
s
–
M
a
r
l
o
v
i
t
s
e
t
a
l
.
[
7
1
]
R
e
t
r
o
s
p
e
c
t
i
v
e
,
c
r
o
s
s
-
s
e
c
t
i
o
n
a
l
H
y
a
l
u
r
o
n
a
n
(
H
y
a
l
o
g
r
a
f
t
C
)
9
2
y
e
a
r
s
2
.
6
2
±
0
.
6
5
K
O
O
S
;
p
a
i
n
6
8
±
2
4
;
s
y
m
p
t
o
m
s
6
2
±
1
5
;
A
D
L
7
5
±
2
2
;
s
p
o
r
t
5
3
±
2
9
;
Q
O
L
7
0
±
2
2
N
e
h
r
e
r
e
t
a
l
.
[
8
2
]
P
r
o
s
p
e
c
t
i
v
e
,
c
a
s
e
s
e
r
i
e
s
H
y
a
l
u
r
o
n
a
n
(
H
y
a
l
o
g
r
a
f
t
C
)
3
6
3
y
e
a
r
s
E
x
c
e
l
l
e
n
t
o
r
G
o
o
d
:
8
7
%
,
a
v
e
r
a
g
e
:
6
0
±
2
5
p
r
e
o
p
e
r
a
t
i
v
e
:
3
9
±
1
9
,
P
o
s
t
-
o
p
e
r
a
t
i
v
e
v
a
l
u
e
s
s
i
g
n
i
ﬁ
c
a
n
t
l
y
i
m
p
r
o
v
e
d
c
o
m
p
a
r
e
d
w
i
t
h
p
r
e
o
p
e
r
a
t
i
v
e
v
a
l
u
e
s
(
p
\
0
.
0
2
)
8
1
±
1
9
p
r
e
o
p
e
r
a
t
i
v
e
:
5
8
±
1
4
,
P
o
s
t
-
o
p
e
r
a
t
i
v
e
v
a
l
u
e
s
s
i
g
n
i
ﬁ
c
a
n
t
l
y
i
m
p
r
o
v
e
d
c
o
m
p
a
r
e
d
w
i
t
h
p
r
e
o
p
e
r
a
t
i
v
e
v
a
l
u
e
s
(
p
\
0
.
0
5
)
7
±
3
p
r
e
o
p
e
r
a
t
i
v
e
:
3
±
2
–
–
–
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a
b
l
e
1
c
o
n
t
i
n
u
e
d
A
u
t
h
o
r
s
S
t
u
d
y
d
e
s
i
g
n
S
c
a
f
f
o
l
d
,
T
e
c
h
n
i
q
u
e
e
t
c
N
F
o
l
l
o
w
-
u
p
I
K
D
C
s
c
o
r
e
L
y
s
h
o
l
m
s
c
o
r
e
C
i
n
c
i
n
n
a
t
i
k
n
e
e
s
c
o
r
e
I
C
R
S
F
u
n
c
t
i
o
n
a
l
s
c
o
r
e
,
e
v
a
l
u
a
t
i
o
n
f
o
r
m
V
A
S
e
t
c
O
t
h
e
r
c
l
i
n
i
c
a
l
o
u
t
c
o
m
e
s
B
a
r
t
l
e
t
t
e
t
a
l
.
[
5
]
P
r
o
s
p
e
c
t
i
v
e
,
r
a
n
d
o
m
i
s
e
d
P
o
r
c
i
n
e
-
d
e
r
i
v
e
d
c
o
l
l
a
g
e
n
I
/
I
I
I
m
a
t
r
i
x
(
M
A
C
I
)
v
s
.
A
C
I
w
i
t
h
a
c
o
v
e
r
m
a
n
u
f
a
c
t
u
r
e
d
f
r
o
m
P
o
r
c
i
n
e
-
d
e
r
i
v
e
d
c
o
l
l
a
g
e
n
I
/
I
I
I
(
M
a
t
r
i
c
e
l
)
4
7
v
s
.
4
4
1
y
e
a
r
–
–
6
4
v
s
.
5
9
N
S
(
m
o
d
i
ﬁ
e
d
)
p
r
e
o
p
e
r
a
t
i
v
e
:
4
5
v
s
.
4
1
N
S
,
P
o
s
t
-
o
p
e
r
a
t
i
v
e
v
a
l
u
e
s
i
n
b
o
t
h
g
r
o
u
p
s
s
i
g
n
i
ﬁ
c
a
n
t
l
y
i
m
p
r
o
v
e
d
c
o
m
p
a
r
e
d
w
i
t
h
p
r
e
o
p
e
r
a
t
i
v
e
v
a
l
u
e
s
(
p
=
0
.
0
0
2
,
0
.
0
1
)
–
4
v
s
.
4
N
S
p
r
e
o
p
e
r
a
t
i
v
e
:
6
v
s
.
6
N
S
,
P
o
s
t
-
o
p
e
r
a
t
i
v
e
v
a
l
u
e
s
i
n
b
o
t
h
g
r
o
u
p
s
s
i
g
n
i
ﬁ
c
a
n
t
l
y
i
m
p
r
o
v
e
d
c
o
m
p
a
r
e
d
w
i
t
h
p
r
e
o
p
e
r
a
t
i
v
e
v
a
l
u
e
s
(
p
=
0
.
0
0
3
,
0
.
0
0
1
)
S
t
a
n
m
o
r
e
f
u
n
c
t
i
o
n
a
l
r
a
t
i
n
g
;
2
v
s
.
2
N
S
p
r
e
o
p
e
r
a
t
i
v
e
:
3
v
s
.
3
N
S
P
o
s
t
-
o
p
e
r
a
t
i
v
e
v
a
l
u
e
s
i
n
b
o
t
h
g
r
o
u
p
s
s
i
g
n
i
ﬁ
c
a
n
t
l
y
i
m
p
r
o
v
e
d
c
o
m
p
a
r
e
d
w
i
t
h
p
r
e
o
p
e
r
a
t
i
v
e
v
a
l
u
e
s
(
p
=
0
.
0
2
,
0
.
0
2
)
M
a
r
c
a
c
c
i
e
t
a
l
.
[
6
8
]
R
e
t
r
o
s
p
e
c
t
i
v
e
,
c
a
s
e
s
e
r
i
e
s
H
y
a
l
u
r
o
n
a
n
(
H
y
a
l
o
g
r
a
f
t
C
)
1
4
1
A
v
e
r
a
g
e
:
3
8
m
o
n
t
h
s
(
2
–
5
y
e
a
r
s
)
S
u
b
j
e
c
t
i
v
e
;
9
2
%
o
f
p
a
t
i
e
n
t
s
i
m
p
r
o
v
e
d
.
a
v
e
r
a
g
e
:
7
9
±
2
0
p
r
e
o
p
e
r
a
t
i
v
e
:
4
0
±
1
4
,
P
o
s
t
-
o
p
e
r
a
t
i
v
e
v
a
l
u
e
s
s
i
g
n
i
ﬁ
c
a
n
t
l
y
i
m
p
r
o
v
e
d
c
o
m
p
a
r
e
d
w
i
t
h
p
r
e
o
p
e
r
a
t
i
v
e
v
a
l
u
e
s
(
p
\
0
.
0
0
0
1
)
.
O
b
j
e
c
t
i
v
e
;
N
o
r
m
a
l
o
r
N
e
a
r
l
y
n
o
r
m
a
l
:
9
6
%
–
–
F
u
n
c
t
i
o
n
a
l
s
t
a
t
u
s
:
7
1
%
o
f
t
h
e
p
a
t
i
e
n
t
s
c
o
u
l
d
d
o
e
v
e
r
y
t
h
i
n
g
o
r
n
e
a
r
l
y
e
v
e
r
y
t
h
i
n
g
(
L
e
v
e
l
s
I
a
n
d
I
I
)
E
u
r
o
Q
o
l
-
E
Q
-
5
D
q
u
e
s
t
i
o
n
n
a
i
r
e
;
7
6
%
a
n
d
8
8
%
o
f
p
a
t
i
e
n
t
s
h
a
d
n
o
p
a
i
n
a
n
d
m
o
r
b
i
l
i
t
y
p
r
o
b
l
e
m
s
.
P
o
s
t
-
o
p
e
r
a
t
i
v
e
v
a
l
u
e
s
(
0
.
7
)
s
i
g
n
i
ﬁ
c
a
n
t
l
y
i
m
p
r
o
v
e
d
c
o
m
p
a
r
e
d
w
i
t
h
p
r
e
o
p
e
r
a
t
i
v
e
v
a
l
u
e
s
(
0
.
9
)
(
p
\
0
.
0
0
0
1
)
–
V
i
s
n
a
e
t
a
l
.
[
1
1
5
]
P
r
o
s
p
e
c
t
i
v
e
,
r
a
n
d
o
m
i
s
e
d
,
c
o
n
t
r
o
l
l
e
d
F
i
b
r
i
n
g
l
u
e
(
T
i
s
s
u
c
o
l
)
v
s
.
a
b
l
a
s
i
v
e
t
e
c
h
n
i
q
u
e
2
5
v
s
.
2
5
1
y
e
a
r
S
u
b
j
e
c
t
i
v
e
;
7
6
±
1
3
v
s
.
6
8
±
1
0
S
i
g
n
i
ﬁ
c
a
n
t
l
y
b
e
t
t
e
r
i
n
A
C
I
i
n
ﬁ
b
r
i
n
g
l
u
e
(
p
\
0
.
0
5
)
p
r
e
o
p
e
r
a
t
i
v
e
:
4
1
±
1
2
v
s
.
4
5
±
1
1
8
6
±
9
v
s
.
7
4
±
1
1
S
i
g
n
i
ﬁ
c
a
n
t
l
y
b
e
t
t
e
r
i
n
A
C
I
i
n
ﬁ
b
r
i
n
g
l
u
e
(
p
\
0
.
0
0
1
)
p
r
e
o
p
e
r
a
t
i
v
e
:
4
8
±
1
1
v
s
.
5
3
±
1
1
–
–
–
T
e
g
n
e
r
a
c
t
i
v
i
t
y
s
c
o
r
e
;
5
.
9
±
0
.
8
v
s
.
4
.
2
±
1
.
1
S
i
g
n
i
ﬁ
c
a
n
t
l
y
b
e
t
t
e
r
i
n
A
C
I
i
n
ﬁ
b
r
i
n
g
l
u
e
(
p
\
0
.
0
1
)
p
r
e
o
p
e
r
a
t
i
v
e
:
3
.
2
±
0
.
8
v
s
.
2
.
3
±
1
.
1
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a
b
l
e
1
c
o
n
t
i
n
u
e
d
A
u
t
h
o
r
s
S
t
u
d
y
d
e
s
i
g
n
S
c
a
f
f
o
l
d
,
T
e
c
h
n
i
q
u
e
e
t
c
N
F
o
l
l
o
w
-
u
p
I
K
D
C
s
c
o
r
e
L
y
s
h
o
l
m
s
c
o
r
e
C
i
n
c
i
n
n
a
t
i
k
n
e
e
s
c
o
r
e
I
C
R
S
F
u
n
c
t
i
o
n
a
l
s
c
o
r
e
,
e
v
a
l
u
a
t
i
o
n
f
o
r
m
V
A
S
e
t
c
O
t
h
e
r
c
l
i
n
i
c
a
l
o
u
t
c
o
m
e
s
C
h
e
r
u
b
i
n
o
e
t
a
l
.
[
2
2
]
P
r
o
s
p
e
c
t
i
v
e
,
u
n
c
o
n
t
r
o
l
e
d
P
o
r
c
i
n
e
c
o
l
l
a
g
e
n
I
/
I
I
I
m
a
t
r
i
x
(
M
A
C
I
)
6
M
i
n
i
m
u
m
o
f
6
m
o
n
t
h
s
–
9
4
(
r
a
n
g
e
,
8
7
–
9
7
)
p
r
e
o
p
e
r
a
t
i
v
e
:
4
6
.
5
(
r
a
n
g
e
,
1
8
–
6
7
)
C
l
i
n
i
c
a
l
e
v
a
l
u
a
t
i
o
n
;
8
.
5
(
r
a
n
g
e
,
6
–
1
0
)
p
r
e
o
p
e
r
a
t
i
v
e
:
4
.
7
(
r
a
n
g
e
,
2
–
6
)
P
a
t
i
e
n
t
s
’
e
v
a
l
u
a
t
i
o
n
;
8
(
r
a
n
g
e
,
6
–
1
0
)
p
r
e
o
p
e
r
a
t
i
v
e
:
2
.
6
(
r
a
n
g
e
,
2
–
4
)
E
v
a
l
u
a
t
i
o
n
f
o
r
m
;
4
n
o
r
m
a
l
k
n
e
e
s
a
n
d
2
n
e
a
r
l
y
n
o
r
m
a
l
k
n
e
e
s
–
T
e
g
n
e
r
a
c
t
i
v
i
t
y
s
c
o
r
e
;
6
.
5
(
r
a
n
g
e
,
5
–
7
)
p
r
e
o
p
e
r
a
t
i
v
e
:
2
.
6
(
r
a
n
g
e
,
1
–
4
)
P
a
v
e
s
i
o
e
t
a
l
.
[
8
5
]
R
e
t
r
o
s
p
e
c
t
i
v
e
,
c
a
s
e
s
e
r
i
e
s
H
y
a
l
u
r
o
n
a
n
(
H
y
a
l
o
g
r
a
f
t
C
)
6
7
M
e
a
n
:
1
7
.
5
m
o
n
t
h
s
S
u
b
j
e
c
t
i
v
e
;
7
8
±
1
8
p
r
e
o
p
e
r
a
t
i
v
e
:
3
7
±
9
,
P
o
s
t
-
o
p
e
r
a
t
i
v
e
v
a
l
u
e
s
s
i
g
n
i
ﬁ
c
a
n
t
l
y
i
m
p
r
o
v
e
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.
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p
r
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p
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v
e
:
5
9
±
1
7
,
P
o
s
t
-
o
p
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ﬁ
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.
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i
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p
r
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p
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.
0
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r
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i
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p
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c
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i
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ﬁ
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c
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e
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123Cartilage Repair Society score (ICRS) score and the
Hospital for Special Surgery (HSS) score between patients
with Hyalograft C and those undergoing ACI procedure.
According to Bartlett et al. [5], no differences were found
in the clinical outcomes such as the Cincinnati Knee
Rating System, Stanmore functional rating system, and
visual analogue score between standard ACI procedure
using a collagen membrane as cover and MACI. The fol-
low-up periods in these comparative studies were short
(1 year).
In a prospective study, 5 years after transplantation of
cell seeded collagen grafts, 8 of 11 patients rated the knee
function better than pre-operatively, and the clinical eval-
uation showed signiﬁcant improvement in the Meyers
score, the Lysholm score and ICRS score [6]. In a multi-
center retrospective cohort study using Hyalograft C with a
follow-up from 2 to 5 years, 91.5% of 141 patients
improved according to the IKDC subjective evaluation,
with patients who had traumatic injuries and osteochon-
dritis dissecans (OCD) reported better improvement than
those who had degenerative lesions [68].
The clinical outcome with MACI membrane by Bartlett
et al. [5] was better in the group of patients aged under
35 years, compared with those aged over 35 years. Patients
who had been treated for lesions larger than 5 cm
2 in size
had poorer clinical outcomes than those with smaller
lesions, although the differences were not statistically
signiﬁcant. Nehrer et al. [82] have also showed that
patients with Hyalograft C below 30 years of age with
single lesions showed signiﬁcantly better improvements
compared with those over 30 years with multiple defects.
They suggest that implantation of Hyalograft C in older
patients or those with multiple defects should only be
carried out in selected patients with high compliance and
lesser expectations with regard to physical activity.
Regardless of the type of scaffolds, the use of tissue-
engineered grafts based on these scaffolds appears to be as
effective as conventional ACI, although none of these
methods so far have been shown to be better.
Complications, graft failures
There are only few serious adverse events reported in the
literature (Table 2). The rate of superﬁcial infection of
patients ranges from 0 to 2%, which is equivalent to that
of patients using the convensional ACI technique [7, 11,
14, 26, 30, 37, 45, 47, 51, 61, 62, 64, 73–77, 87–89,
119]. There are no patients of septic arthritis, which
ranged from 0–3% of patients using the convensional
ACI technique [7, 11, 14, 26, 30, 37, 45, 47, 51, 61, 62,
64, 73–77, 87–89, 119]. Apart from two studies reporting
the use of periosteal ﬂaps [83, 85], the frequency of
complications such as arthroﬁbrosis or graft failure
appear to be lower (0–18%) than those reported to occur
in 3–36% of patients using the conventional ACI tech-
nique [7, 11, 14, 26, 30, 37, 45, 47, 51, 61, 62, 64, 73–
77, 87–89, 119]. The frequency of reoperations related to
the implantation is also lower (0–16%) than those
reported to occur in 2–36% of patients using the con-
ventional ACI technique [7, 11, 14, 26, 30, 37, 45, 47,
51, 61, 62, 64, 73–77, 87–89, 119]. Complications known
to be associated with ACI include adhesions, arthroﬁ-
brosis, periosteal hypertrophy, and graft failure. Using
scaffold techniques, periosteal hypertrophy does not occur
due to the fact that in the majority of procedures, peri-
osteum is not used. Periosteal hypertrophy is a common
complication of ACI [11, 37, 42, 45, 61, 73, 74, 76, 78,
87, 119]. According to the only study, which compares
the results of MACI (Hyalograft C) and conventional
ACI (Carticel
; Genzyme, Cambridge, Massachusetts,
USA) by Manfredini et al. [65], however, neither the
patients with Hyalograft C nor those with conventional
ACI reported any serious complications. This literature
review clearly shows the need for prospective, random-
ized studies with sufﬁcient number of patients. At this
stage of development it appears that new techniques with
scaffolds seem to reduce complications or graft failures
caused by a periosteal ﬂap.
Arthroscopic and histological ﬁndings
Nine of the fourteen articles have reported second-look
arthroscopicandhistologicalﬁndings(Table 2)[5,6,36,68,
69, 83–85, 115]. These arthroscopic assessments indicated
that 66–100% of available patients had a normal or nearly
normal outcome in the ICRS visual score or Brittberg scale.
Histological analysis have shown that the frequency of
hyaline-like repair with good integration into the surround-
ing tissue was ranged 0–100% (2–22 biopsies, 3–30 months
after operation). The wide difference of hyaline-like repair
ratio between these published studies may be due to the
differences in the number of biopsies and the time of biop-
sies. It is well known that the validity and signiﬁcance of a
biopsy is limited by the number of biopsies taken and the
time after surgery, and that a biopsy result presents rather a
trend [6]. ACI using periosteum has consistently reported
more than 34% of the biopsy specimens had at least some
hyaline cartilage present, although few were composed
totally of hyaline cartilage[10,11,37,44–47,51,61,87,88,
95, 109]. There is not sufﬁcient evidence to state that scaf-
fold methods result in homogeneous distribution of cells in
the scaffold, maintenance of the chondrocyte phenotype and
more hyaline cartilage, all three potential advantages over
ACI. Despite many positive clinical results published, the
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i
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i
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c
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e
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c
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i
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r
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p
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i
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p
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p
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p
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i
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.
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with normal hyaline articular cartilage.
Follow-up biopsies from conventional ACI grafts
showed the four cartilage layers composed of ﬁbrous
periosteal remnant cover, transitional repair tissue, deep
hyaline-like repair tissue, and calciﬁed layer [74, 94]. On
the other hand, histological evaluation of the samples of
ﬁbrin scaffold by Visna et al. [115] demonstrated only two
layers of hyaline-like cartilage and calciﬁed layer. Differ-
ing histological ﬁndings between the conventional ACI and
the scaffold technique can be explained by the different
surgical technique, where the ﬁrst two layers in ACI
technique developed as a consequence of periostal use for
chondrocyte ﬁxation [115].
Hollander et al. [49] reported a detailed study of the
maturation of Hyalograft C once implanted into humans.
They has shown that hyaline cartilage regeneration can be
observed less than one year after implantation of Hyalo-
graft C and that there is progressive maturation of the
implants, even in joints showing signs of osteoarthritis.
This outcome was observed in 10 of 23 patients, whereas in
a further 10 patients, the repair tissue was ﬁbro-cartilage,
and in the remaining 3, there was a mixed type of cartilage
[49].
From a cohort of 56 MACI patients, Zheng et al. [120]
examined the phenotype of chondrocytes seeded on type I/
III collagen scaffold, and conducted progressive histolog-
ical assessment over a period of 6 months. Their data
showed that chondrocytes on the collagen scaffold
appeared spherical, well integrated into the matrix, and
maintained the chondrocyte phenotype as evidenced by
aggrecan, type II collagen, and S-100 expression. Pro-
gressive histological evaluation of the biopsies showed the
formation of cartilage-like tissue as early as 21 days, and
75% hyaline-like cartilage regeneration after 6 months.
While ﬁbrin sealant appeared to act as an adhesive sub-
stance for the seeded ACI-Maix collagen scaffold, it also
facilitated the maturation of the implanted chondrocytes
into functional cartilage [120].
According to Pavesio et al. [85], comparison of the
clinical outcomes with arthroscopic assessment and histo-
logical ﬁndings showed that hyaline-like regenerated tissue
correlated with the most favorable clinical results. How-
ever, Behrens et al. [6] demonstrated that some patients can
have a good clinical outcome despite generating ﬁbro-
cartilage at the repair site. The correlation between clinical
outcome and histologic grading remains controversial.
Magnetic resonance imaging
Magnetic resonance imaging (MRI) is useful for the eval-
uation of the morphologic status of the repair tissue [91,
93]. This method can be considered as a noninvasive
alternative to second-look arthroscopy. Current MRI
techniques such as high-resolution, T2 mapping, and T1
mapping using delayed gadolinium-enhanced MRI
(dGEMRIC) have signiﬁcantly improved during recent
years [111–113]. Six of the fourteen studies have published
MRI ﬁndings (Table 2)[ 22, 36, 65, 71, 84, 112]. The MRI
analysis at 6, 12, 24 months after implantation has shown
good defect ﬁlling with good integration into the sur-
rounding tissue in more than 60% of patients [22, 36, 65,
71, 84]. In addition, repair tissue has shown a gradual
maturation over time [36, 111, 112]. Similar ﬁndings have
been reported in studies with conventional ACI [13, 44, 46,
89, 95, 108, 109]. Marlovits et al. [70] found using high-
resolution MRI that the implantation and ﬁxation of
chondrocytes seeded on type I/III collagen scaffold with
ﬁbrin glue and with no further surgical ﬁxation leads to a
high attachment rate (88%) 35 days after the implantation.
According to the study that compared the results of
Hyalograft C with those of Carticel by Manfredini et al.
[65], MRI analysis did not reveal any signiﬁcant differ-
ences, although the images of patients with Carticel
showed a greater tendency towards hypertrophic growth of
the repair tissue probably due to periosteal hypertrophy.
Some authors [65, 71] have reported a signiﬁcant correla-
tion between the clinical outcome and the MRI analysis
scores.
Conclusion and future considerations on scaffolds
for cartilage repair
The tissue-engineering methods with scaffolds including
the arthroscopic technique are less invasive because there
is no need to harvest periosteum. These methods reduce
surgical time, morbidity, and risks of periosteal hypertro-
phy and postsurgical adhesions substantially. The technical
and theoretical advantages of scaffold techniques have led
to the technique being favored by surgeons performing
chondrocyte implantation. However, in this review of the
short- or mid-term, clinical and histological results pub-
lished by various studies, none of these methods were
judged to be better than conventional ACI. In addition,
there was no obvious ranking among the scaffolds avail-
able for clinical use at the present time. There is probably
not an even distribution of chondrocytes. These methods
seem to promote chondrocyte differentiation and formation
of cartilage matrix, but so far, they have not resulted in
improved clinical results.
The ultimate aim of cartilage treatment is the restoration
of normal knee function by regeneration of hyaline carti-
lage, and to achieve a complete integration of the new
cartilage to the surrounding cartilage and underlying
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123bone. Promising development is underway with regards to
cell-based techniques in combination with scaffolds,
growth factors and possibly gene therapy. Unfortunately,
this effort has not been followed by appropriate or sufﬁ-
cient clinical studies to assess these new methods or
compare them with available procedures.
The methodological level of the clinical papers is in
general low. Jacobsen et al. [54] showed very low meth-
odological quality of most studies on cartilage repair. So
far, only three prospective, randomized or non-randomized
comparative studies have been published. The generally
low methodological quality of many studies shows that
caution is required when interpreting results after surgical
cartilage repair. Firm recommendations on which cartilage
repair procedure is to be preferred is currently not known
on the basis of these studies.
Valid clinical answers in this ﬁeld will only be the
results of a combination of randomized control trials
(RCTs). Further, long-term follow up is needed to deter-
mine whether articular cartilage repair with scaffold is a
valid alternative as ﬁrst line of treatment of larger cartilage
defects compared with ACI.
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